AI-driven leap: Juvenescence expands R&D capabilities with Ro5 acquisition
Longevity Technology - 05-Jun-2025Ro5’s AI platform boosts Juvenescence’s age-related drug pipeline and fuels UAE healthtech push
Juvenescence
Developing therapies against different aging related diseases
Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.
Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life.
By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.
Juvenescence Executive Team
- Greg Bailey, Co-founder, Executive Chairman
- Jim Mellon, Co-founder, Deputy Chairman
- Declan Doogan, Co-founder, Board Member
- Richard Marshall, Chief Executive Officer
- Gillian Dines, Chief Science Officer
- Steve Felstead, Chief Medical Officer
- Jeff Madwed, Senior Project Lead
- Rosalba Perrone, Senior Research Scientist
- Kersten Small, Project Leader
- David Gill, Chief Financial Officer
- Alexander Pickett, Managing Director
Visit website: https://www.juvlabs.com/
Details last updated 04-May-2019
Juvenescence News
UK biotech Juvenescence secures over $150m to develop therapies
Endpoints News - 21-May-2025Juvenescence expands pipeline and UAE presence with new funding to tackle age-related diseases
AI alliance to redefine the future of ageing and therapeutics
Juvenescence - 16-Apr-2025M42 and Juvenescence join forces to accelerate precision medicine and longevity
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Summary of Jim Mellon presentation at Longevity Med Summit
Live Forever Club - 19-May-2023Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry
Display all news
Mentioned in this Resource
Jim Mellon
British entrepreneur, author and philanthropist with interests across a number of industries
Juvenescence is also referenced in the following:
Selah Therapeutics
Company focused on novel ketone-based therapies for the treatment of heart diseases
Juvenescence Creations
Investing in the Future of Longevity – the Ketone Chapter
10-May-2022
Juvenescence webinar about the latest research and developments on future of longevity investment
Other people at Juvenescence
